ReviewFrontiers in chemistry2015
Synthetic self-adjuvanting glycopeptide cancer vaccines.
Review in Frontiers in chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 64 citations in OpenAlex.
- Solid-Phase Glycolipid Synthesis Expedites Liposome Functionalization.Journal of the American Chemical Society · 2026Article
- Review
- Development of Methamphetamine Conjugated Vaccine through Hapten Design: In Vitro and In Vivo Characterization.Vaccines · 2023Article
- The macrophage infectivity potentiator ofFrontiers in immunology · 2023Article
- Preclinical Assessment of Immunogenicity and Protectivity of Novel ROR1 Fusion Proteins in a Mouse Tumor Model.Cancers · 2022Article
- Precise immunological evaluation rationalizes the design of a self-adjuvanting vaccine composed of glycan antigen, TLR1/2 ligand, and T-helper cell epitope.RSC advances · 2022Article
- Glycoconjugate Nanoparticle-Based Systems in Cancer Immunotherapy: Novel Designs and Recent Updates.Frontiers in immunology · 2022Review
- Design, synthesis, and initial immunological evaluation of glycoconjugates based on saponin adjuvants and the Tn antigen.Chemical communications (Cambridge, England) · 2021Article
- Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines.RSC advances · 2021Article
- Synthesis ofTetrahedron letters · 2021Article
- Synthetic protein conjugate vaccines provide protection againstProceedings of the National Academy of Sciences of the United States of America · 2021Article
- Statistical and Artificial Neural Network Approaches to Modeling and Optimization of Fermentation Conditions for Production of a Surface/Bioactive Glyco-lipo-peptide.International journal of peptide research and therapeutics · 2021Article
- Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.Seminars in immunology · 2020Review
- Article
- Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines.Molecules (Basel, Switzerland) · 2018Review
- A One-Step Chemoenzymatic Labeling Strategy for Probing Sialylated Thomsen-Friedenreich Antigen.ACS central science · 2018Article
- Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.Chembiochem : a European journal of chemical biology · 2018Article
- Targeting cancer-specific glycans by cyclic peptide lectinomimics.Amino acids · 2017Article
- Synthesis and Evaluation of GM2-Monophosphoryl Lipid A Conjugate as a Fully Synthetic Self-Adjuvant Cancer Vaccine.Scientific reports · 2017Article
- Immunological characterization of a rigid α-Tn mimetic on murine iNKT and human NK cells.Glycoconjugate journal · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to changes in glycosyltransferase expression during oncogenesis, the glycoproteins of cancer cells often carry highly truncated carbohydrate chains compared to those on healthy cells. These glycans are known as tumor-associated carbohydrate antigens (TACAs), and are prime targets for use in vaccines for the prevention and treatment of cancer. Herein, we review the state-of-the-art in targeting the immune system toward tumor-associated glycopeptide antigens via synthetic self-adjuvanting vaccines, in which the antigenic and adjuvanting moieties of the vaccines are present in the same molecule. The majority of the self-adjuvanting glycopeptide cancer vaccines reported to date employ antigens from mucin 1, a protein which is highly over-expressed and aberrantly glycosylated in many forms of cancer. The adjuvants used in these vaccines predominantly include lipopeptide- or lipoamino acid-based TLR2 agonists, although studies investigating stimulation of TLR9 and TLR4 are also discussed. Many of these adjuvants are highly lipophilic, and, upon conjugation to antigenic peptides, provide amphiphilic vaccine molecules. The amphiphilic nature of these vaccine constructs can lead to the formation of higher-order structures by vaccines in solution, which are likely to be important for their efficacy in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.